Abstract
The matrix stiffness-related signature not only serves as a robust prognostic tool but also aids in identifying immune characteristics and optimizing therapeutic strategies, thus advancing personalized medicine for patients with HCC.
Introduction
Hepatocellular Carcinoma (HCC) typically develops within a background of chronic liver disease, where the histological progression from hepatitis to fibrosis and cirrhosis fundamentally alters the biophysical environment. A hallmark of this progression is increased matrix stiffness. While traditional prognostic models for HCC often focus on biochemical or metabolic markers, the mechanical environment of the tumor microenvironment (TME) is a critical driver of cancer progression and immune evasion. This study aims to quantify these mechanical influences by identifying molecular subtypes and gene signatures specifically related to matrix stiffness.
Multi-Omics Subtyping and Signature Development
To capture the complex interplay between tissue mechanics and molecular biology, researchers integrated mRNA, miRNA, DNA methylation, and somatic mutation data from TCGA-LIHC cohorts. Using ten different clustering algorithms, they identified three distinct molecular subtypes with varying clinical profiles.
Building upon these subtypes, the team developed a "Matrix Stiffness-Related Signature" (MSRS). They evaluated 101 combinations of machine learning algorithms—including Lasso, Ridge, and Random Survival Forests—to identify the most accurate predictive model. The combination of Stepwise Cox and CoxBoost yielded the highest C-index, resulting in a robust 57-gene signature.
The Prognostic Power of the MSRS
The 57-gene MSRS was validated across multiple independent datasets from the USA, China, and Japan. It consistently outperformed 47 previously published HCC signatures in predicting overall survival. Patients categorized into the "high-stiffness" subtype (CS1) exhibited significantly poorer survival outcomes and a higher frequency of TP53 mutations.
Further analysis using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) confirmed that the expression of these signature genes is spatially correlated with malignant regions and markers of extracellular matrix remodeling, such as Fibronectin and α-SMA.
Mechanistic Insights: The PPARG-MAPK Axis
A central discovery of this research is the role of PPARG as a critical transducer of mechanical signals. Experimental validation using silicon gels of varying stiffness (0.5 kPa to 16 kPa) demonstrated that increased stiffness directly upregulates PPARG expression. This activation triggers the MAPK signaling pathway (specifically ERK and JNK phosphorylation), which promotes cell proliferation, lipid metabolism, and cancer stem-cell properties.
Additionally, high-stiffness tumors showed an "immunosuppressive" landscape, characterized by higher levels of M0 macrophages and lower levels of monocytes, suggesting that matrix stiffness actively helps cancer cells evade the immune system.
Clinical Implications and Therapeutic Potential
The study identifies a significant therapeutic opportunity: targeting the PPARG-MAPK axis with the MEK inhibitor trametinib can reverse stiffness-mediated therapy resistance. This effect was particularly pronounced when combined with standard treatments like sorafenib or cisplatin. Consequently, the MSRS could serve as a companion diagnostic to guide personalized HCC therapy.
Conclusion
By bridging the gap between tissue biophysics and molecular oncology, this study provides a comprehensive map of how matrix stiffness drives HCC progression. The 57-gene MSRS offers a powerful new tool for predicting patient prognosis and optimizing therapeutic response, advancing the goal of personalized medicine for liver cancer patients.
Summary updated